Overview

Niraparib + Dostarlimab + RT in Pancreatic Cancer

Status:
Active, not recruiting

Trial end date:
2026-10-01

Target enrollment:

Participant gender:

Summary

This research is being done to see how the combination of dostarlimab, niraparib, and radiation therapy works in controlling metastatic pancreatic cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborator:

Tesaro, Inc.

Treatments:

Niraparib